DKTK-Studienregister

Detailsuche

Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.

» Hämatologische Neoplasien » Verschiedene Neoplasien

Alle Linien

LCH-REG-DE 2013
Deutsches Register für LCH im Kindes- und Jugendalter (Aktiv)

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (Aktiv)

Erstlinie

EMAA (9345)
Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A (Aktiv)

Zweitlinie oder später

Bayer 18117
An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 (Aktiv)

CLDK378A2407
study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)

GC-LTFU-001
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)

HD-CAR-1/V03
Treatment of patients with CD19+ hematologic disease with T lymphocytes transduced retrovirally with a third generation CAR (Aktiv)

LOXO-IDH-20001 (I9Y-OX-JDHB)
Eine Phase-I-Studie mit oralem LY3410738 bei Patienten mit fortgeschrittenen hämatologischen Malignomen mit IDH1- oder IDH2-Mutationen (Aktiv)